Literature DB >> 30720897

Reply to Woltsche N. et al. Managing adverse effects by dose reduction during routine treatment of locally advanced basal cell carcinoma with the hedgehog inhibitor vismodegib: a single-centre experience.

M Scalvenzi1, C Costa1, M Cappello1, A Villani1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30720897     DOI： 10.1111/jdv.15469

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN： 0926-9959            Impact factor:   6.166


× No keyword cloud information.
  5 in total

Review 1.  Using drug scheduling to manage adverse events associated with hedgehog pathway inhibitors for basal cell carcinoma.

Authors:  John T Lear; Reinhard Dummer; Alexander Guminski
Journal:  Oncotarget       Date:  2021-12-21

Review 2.  Long-Term Management of Advanced Basal Cell Carcinoma: Current Challenges and Future Perspectives.

Authors:  Markus V Heppt; Christoffer Gebhardt; Jessica C Hassel; Mareike Alter; Ralf Gutzmer; Ulrike Leiter; Carola Berking
Journal:  Cancers (Basel)       Date:  2022-09-20       Impact factor: 6.575

3.  Low-Dose Vismodegib as Maintenance Therapy After Locally Advanced Basal Cell Carcinoma Complete Remission: High Efficacy with Minimal Toxicity.

Authors:  Massimiliano Scalvenzi; Milena Cappello; Claudia Costa; Gabriella Fabbrocini; Mariaantonietta Luciano; Alessia Villani
Journal:  Dermatol Ther (Heidelb)       Date:  2020-04-02

Review 4.  Sonidegib: Safety and Efficacy in Treatment of Advanced Basal Cell Carcinoma.

Authors:  Alessia Villani; Gabriella Fabbrocini; Claudia Costa; Massimiliano Scalvenzi
Journal:  Dermatol Ther (Heidelb)       Date:  2020-04-15

5.  Long-Term Efficacy of Vismodegib After its Withdrawal and Patients' Health-Related Quality of Life Using the Dermatology Life Quality Index (DLQI).

Authors:  Alessia Villani; Matteo Megna; Gabriella Fabbrocini; Milena Cappello; Maria Antonietta Luciano; Claudia Costa; Massimiliano Scalvenzi
Journal:  Dermatol Ther (Heidelb)       Date:  2019-09-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.